Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK considers gauging latent vCJD infection with tests on all postmortems

This article was originally published in Clinica

Executive Summary

The UK government is considering extending postmortem examinations with tests for variant Creutzfeldt-Jakob disease (vCJD), in order to better gauge the extent of latent infection across the entire population. Concerned that 166 UK deaths to date may not reflect the true prevalence, with the significant risk that this poses to transmission through surgery and blood transfusion, the Department of Health (DoH) wants postmortems to include tests on tissues that are known to accumulate the prion protein responsible for vCJD, such as the spleen and the brain. Some 115,000 postmortems are ordered by coroners every year in England alone. The Coroners' Society for England and Wales has criticised the initiative as "inappropriate", but the Health Protection Agency and DoH are reportedly keen to develop the plans and are assessing the practical and legal implications.

You may also be interested in...



Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.

Topics

UsernamePublicRestriction

Register

MT046217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel